|
20 December 2000
SENIOR APPOINTMENTS AT ASTRAZENECA |
AstraZeneca today announced the appointment of Bruno Angelici as Executive Vice President, International Sales and Marketing in succession to Mike O'Brien who is retiring.
|
 |
19 December 2000
ASTRAZENECA WINS LOSEC® PATENT LITIGATION IN CANADA |
The Federal Court of Canada has ruled in favour of AstraZeneca in litigation between AstraZeneca and RhoxalPharma Inc. under the Patented Medicines (Notice Of Compliance) Regulations.
|
|
14 December 2000
ASTRAZENECA GAINS JAPANESE APPROVAL FOR TWO MAJOR TREATMENTS - TWO MORE EXPECTED BEFORE YEAR END |
AstraZeneca today announced it has received approval from the Japanese Ministry of Health and Welfare (MWH) for Seroquel®, one of its major pharmaceuticals, and two significant line extensions for omeprazole, the company's largest product worldwide. In addition, AstraZeneca expects two further major new pharmaceuticals to be approved in Japan before the end of 2000.
|
|
12 December 2000
ASTRAZENECA REPORTS CONTINUED STRONG PROGRESS ACROSS R&D PORTFOLIO |
AstraZeneca today presents an R&D update to a meeting of analysts, at its Mölndal site in Sweden.
|
|
7 December 2000
ASTRAZENECA RELEASES ENCOURAGING PHASE III DATA ON ICI182780 (FASLODEX®) - A NEW TYPE OF ADVANCED BREAST CANCER DRUG OFFERING A POTENTIAL NEW OPTION TO ONCOLOGY COMMUNITY |
Data presented today at the 23rd annual San Antonio Breast Cancer Symposium suggest that AstraZeneca's ICI182780 (Faslodex®) is at least as effective as Arimidex® , the most widely prescribed aromatase inhibitor, in treating advanced breast cancer in post-menopausal women who have failed initial hormonal treatment.
|
|
21 November 2000
ASTRAZENECA FILES ZOMIG® NASAL SPRAY IN EUROPE |
AstraZeneca announced today that it has submitted its first regulatory application in Europe for Zomig (zolmitriptan) Nasal Spray for the acute treatment of migraine with or without aura. This new treatment will be reviewed under the Mutual Recognition procedure with Sweden acting as the reference member state. This is the first filing of a second-generation triptan for a nasal spray formulation.
|
|
17 November 2000
SWEDISH COURT RULES IN ASTRAZENECA's FAVOUR IN OMEPRAZOLE SPC CASE |
AstraZeneca today announced that the Stockholm District Court has ruled that Scand Pharm's generic omeprazole product infringes AstraZeneca's Supplementary Patent Certificate (SPC) for omeprazole, which provides protection until November 15, 2002.
|
|
15 November 2000
ASTRAZENECA REMAINS COMMITTED TO STROKE TREATMENT RESEARCH FOLLOWING STUDY FINDINGS FOR ZENDRA |
AstraZeneca today announced that development of Zendra (clomethiazole) has been stopped following analysis of findings from the Class-I study which showed no efficacy benefits for patients suffering acute cases of stroke.
|
|
13 November 2000
DEALINGS COMMENCE IN SYNGENTA AG |
AstraZeneca announces that dealings have commenced in shares of Syngenta AG.
|
|
13 November 2000
SYNGENTA SHARES PRICED AT CHF 85 FOR GLOBAL SECONDARY OFFERING |
Not for distribution or release in whole or in part into or from the United States, Canada, Australia or JapanAstraZeneca announces that AstraZeneca, Novartis, Syngenta and the Joint Global Co-ordinators have set a price of CHF 85 per share (equivalent to approximately £33.65 and 479.88 SEK per share) and USD 9.63 per ADS for the Global Secondary Offering of Syngenta shares. The price per ADS is based upon the noon buying rate of the New York Federal Reserve Bank on 10 November 2000 of CHF 1.7657 to USD 1. Trading in Syngenta shares is expected to commence on the Swiss, London and Stockholm Stock Exchanges, and Syngenta ADSs on the New York Stock Exchange on 13 November 2000.
|
|
6 November 2000
ASTRAZENECA RECEIVES FDA APPROVAL FOR 72-HOUR INFUSION OF NAROPIN FOR POST-OPERATIVE PAIN MANAGEMENT |
AstraZeneca today announced that it has received approval from the US Food and Drug Administration for 72-hour infusion of Naropin®, a long-acting anaesthetic indicated for the production of local or regional anaesthesia for surgery, postoperative pain management and for obstetrical procedures.
|
|
2 November 2000
FTC CLEARS SPIN-OFFS AND COMBINATION OF ASTRAZENECA'S AGROCHEMICALS BUSINESS AND NOVARTIS' AGRIBUSINESS |
AstraZeneca and Novartis AG today announced that the United States Federal Trade Commission (FTC) has approved a consent decree in connection with the spin-offs of AstraZeneca's agrochemicals business and Novartis' Agribusiness and the combination of these businesses to create Syngenta AG.
|
|
30 October 2000
ASTRAZENECA, NOVARTIS AND SYNGENTA ANNOUNCE SYNGENTA GLOBAL SECONDARY OFFER PRICE RANGE AT CHF 85 TO 105 |
AstraZeneca announces that AstraZeneca, Novartis and Syngenta have set a price range of CHF 85 and CHF 105 (equivalent to approximately £32.50 to £40.10 and SEK 475 to SEK 587 ) per share for the Global Secondary Offering of Syngenta shares.
|
|
30 October 2000
DIVESTMENT OF ZENECA's ACETOCHLOR BUSINESS |
AstraZeneca PLC announces that Zeneca Agrochemicals has agreed to sell its worldwide acetochlor herbicide business to Dow Agrosciences LLC.
|
|
26 October 2000
ASTRAZENECA TO OUTSOURCE GLOBAL IT INFRASTRUCTURE SERVICES TO IBM |
AstraZeneca today announced that it has identified IBM as its preferred supplier of global Information Technology (IT) infrastructure services. This is subject to signature of a contract, the key terms of which have already been established in principle with IBM. A further announcement will be made once a contract has been signed.
|
|
20 October 2000
JOINT FDA ADVISORY COMMITTEE CONFIRMS OTC PRILOSEC® (OMEPRAZOLE) SAFETY AND EFFICACY |
Requests Further Data
|
|
17 October 2000
ASTRAZENECA SIGNS LICENSING AGREEMENT WITH NORTRAN |
AstraZeneca PLC ('AstraZeneca') announced today the execution of a licensing agreement with Nortran Pharmaceuticals Inc. ('Nortran'), a Canadian based drug discovery company. Nortran will grant AstraZeneca an exclusive world-wide licence to market a novel antiarrhythmic drug candidate in exchange for upfront, milestone and royalty payments. AstraZeneca will pay for development and marketing costs. This agreement further strengthens AstraZeneca's cardiovascular portfolio.
|
|
12 October 2000
TWO STUDIES REPORT ENCOURAGING NEW DATA ON LONG-TERM EFFECTS OF PULMICORT® ON ASTHMA CONTROL AND GROWTH IN CHILDREN |
Two landmark studies reported today in the New England Journal of Medicine show encouraging new data on asthma management and children's growth with long-term use of Pulmicortâ (budesonide), an inhaled corticosteroid, made by AstraZeneca. Given the chronic nature of persistent asthma and the likely need for medications to be used for long periods of time, each of the studies -- one conducted by the National Institutes of Health (NIH), the other by world-renown asthma specialists in Denmark -- examined the long-term effects of the inhaled corticosteroid, budesonide.
|
|
11 October 2000
ASTRAZENECA AND NOVARTIS SHAREHOLDERS APPROVE SYNGENTA TRANSACTION |
AstraZeneca PLC announces that, at its Extraordinary General Meeting held in London earlier today, shareholder approval was given for the declaration and payment by the AstraZeneca Board of a dividend of Syngenta shares to holders of AstraZeneca shares on the relevant record date. The approval of this dividend will facilitate implementation of the previously announced proposed demerger of Zeneca Agrochemicals and its merger with Novartis Agribusiness to form Syngenta.
|
|
9 October 2000
ASTRAZENECA RECEIVES FURTHER JUDGEMENT IN AUSTRALIAN OMEPRAZOLE PATENT DISPUTE |
AstraZeneca today announced that it will seek special leave to appeal against a judgement delivered in the Full Federal Court of Australia in Sydney in a dispute with the generic pharmaceutical company, Alphapharm Pty Limited, about the formulation patent for omeprazole - the substance used in Losec® , a treatment for acid-related disorders, such as peptic ulcers.
|
|
27 September 2000
'ZOLADEX' AS EFFECTIVE AS 'STANDARD' CHEMOTHERAPY IN EARLY BREAST CANCER |
New data pave the way for increased treatment choice in early disease
|
|
20 September 2000
ASTRAZENECA FILES LAWSUIT AGAINST MUTUAL PHARMACEUTICAL |
AstraZeneca announced today that it has filed a lawsuit in Pennsylvania against Mutual Pharmaceutical Company, Inc. for patent infringement.
|
|
19 September 2000
ASTRAZENECA RETAINS US PATENT RIGHTS TO WORLD'S LEADING BREAST CANCER DRUG--NOLVADEX® |
The Federal District Court in Boston has ruled that AstraZeneca's US patent covering its leading breast cancer drug Nolvadex® (tamoxifen) is valid and enforceable. In reaching this decision, District Judge Reginald Lindsay and a jury rejected the patent challenge asserted by the generic drug company, Pharmachemie B.V. As a result, the sale of tamoxifen citrate in the United States by Pharmachemie is prohibited until AstraZeneca's patent expires.
|
|
18 September 2000
ASTRAZENECA CIRCULATES SYNGENTA MERGER INFORMATION TO SHAREHOLDERS |
EGM NOTICE
|
|
8 September 2000
ASTRAZENECA FILES LAWSUIT AGAINST MYLAN |
AstraZeneca today announced that it has filed a lawsuit in New York against Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc. (Mylan) for patent infringement.
|
|
6 September 2000
ASTRAZENECA RECEIVES FDA APPROVAL TO MARKET ATACAND HCT™ |
AstraZeneca announced today the approval of Atacand HCT™ (candesartan cilexetil-hydrochlorothiazide) by the U.S. Food and Drug Administration (FDA) for second-line treatment of hypertension. Atacand HCT combines the angiotensin II receptor blocker (ARB) Atacand® with the diuretic hydrochlorothiazide, providing physicians with another treatment option for those patients who are unable to control their hypertension with a single agent.
|
|
4 September 2000
FDA APPROVES ARIMIDEX - A NEW FIRST LINE TREATMENT OPTION FOR BREAST CANCER |
AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has approved its breast cancer treatment Arimidex™ as a new treatment option for post-menopausal women first diagnosed with advanced or locally advanced breast cancer whose cancers are hormone receptive. Arimidex is the first aromatase inhibitor to be approved for first-line treatment in the U.S.
|
|
29 August 2000
ASTRAZENECA RECEIVES FIRST APPROVAL FOR SYMBICORT TURBUHALER® FOR THE TREATMENT OF ASTHMA |
AstraZeneca has gained its first approval for Symbicort Turbuhalerv® , a new and innovative asthma treatment. Containing the corticosteroid budesonide and fast and long-acting bronchodilator formoterol in a single inhaler (Turbuhaler® ), Symbicort® is being hailed as a significant new step in the field of asthma management.
|
|
9 August 2000
FDA APPROVES PULMICORT RESPULES - FOR CHILDREN AND INFANTS |
AstraZeneca today announced that Pulmicort Respules (budesonide inhalation suspension), its new asthma medication for young children and infants, is now approved by the U.S. Food and Drug Administration (FDA). As the first and only asthma treatment approved for children and infants as young as 12 months, Pulmicort Respules represents an innovative approach to inhaled corticosteroid delivery in young children and is the first and only corticosteroid to be available as a nebulized formulation. Nebulization is a process that converts the liquid medication to a fine mist which the young child can inhale through a tiny facemask or mouthpiece. Previously, inhaled corticosteroid therapy was only available for children four years of age and older and typically administered with an asthma inhaler which young children often were not able to use properly.
|
|
1 August 2000
ASTRAZENECA HALF YEAR RESULTS FIGURES |
Consolidated Profit and Loss Account. Download PDF (44Kb)
|
|
1 August 2000
ASTRAZENECA HALF YEAR RESULTS NARRATIVE |
Profit before tax up 19 per cent; EPS up 18 per cent. Download PDF (38Kb)
|
|
31 July 2000
ASTRAZENECA CONTINUES RAPID DEVELOPMENT OF NEW CHOLESTEROL LOWERING DRUG WITH £28.5M MANUFACTURING PLANT INVESTMENT |
AstraZeneca today kept up the rapid pace of development of ZD4522, a new statin for lowering cholesterol, by announcing a £28.5m investment to build a new bulk medicine manufacturing plant at its Avlon Works, Severnside, near Bristol.
|
|
31 July 2000
ASTRAZENECA ANNOUNCES APPOINTMENT OF GLOBAL E-BUSINESS VICE PRESIDENT |
AstraZeneca today announced the appointment of Kathleen Sheehan to the position of Vice President, Global eBusiness, reporting to John Patterson, Executive Vice President of Product Strategy & Licensing.
|
|
28 July 2000
ASTRAZENECA MERGES JAPANESE SUBSIDIARIES |
AstraZeneca and Sumitomo Chemical Company Limited, of Osaka, today announced an agreement to merge AstraZeneca K.K. and Zeneca Yakuhin K.K from October 1, (2000). The shareholding of the merged company, AstraZeneca K.K, will be owned 80 per cent by AstraZeneca and 20 per cent by Sumitomo Chemical Company.
|
|
26 July 2000
EUROPEAN COMMISSION APPROVES SYNGENTA MERGER |
AstraZeneca and Novartis announced today that the European Commission (EC) has cleared the planned merger of the Zeneca Agrochemicals business with the Novartis Agribusiness to form Syngenta AG, the world's first global dedicated agribusiness company.
|
|
3 July 2000
NOLVADEX RECEIVES NEW FDA APPROVAL FOR USE IN PATIENTS WITH DUCTAL CARCINOMA IN SITU (DCIS) |
AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has approved its breast cancer drug Nolvadex to reduce the risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation. Nolvadex is the first medication to be approved for DCIS, which accounts for nearly 20 per cent of all newly diagnosed breast cancer cases
[1].
|
|
29 June 2000
ASTRAZENECA's NEW STATIN SHOWS POTENTIAL TO IMPROVE TREATMENT FOR THE WORLD's LEADING CAUSE OF DEATH |
The first phase II clinical trial data for ZD4522, AstraZeneca's new statin, were presented today at the XIIth International Symposium on Atherosclerosis in Stockholm, demonstrating its potential to be a highly effective and well tolerated alternative to currently available statins
[1].
|
|
27 June 2000
ASTRAZENECA EXPANDS US PRESENCE WITH NEW $100M RESEARCH CENTRE |
AstraZeneca today announced the opening of its newest research centre, AstraZeneca R&D Boston. The $100 million research centre houses 130 scientists researching infectious diseases, cancer and high-throughput screening technologies that enable novel, scientific approaches to pharmaceutical research.
|
|
21 June 2000
ASTRAZENECA FILES LAWSUIT AGAINST LEK PHARMACEUTICAL AND CHEMICAL COMPANY D.D. |
AstraZeneca today announced that it has filed a lawsuit in New York against LEK Pharmaceutical and Chemical Company d.d. (LEK) and its US subsidiary, LEK USA, Inc. for patent infringement.
|
|
5 June 2000
ASTRAZENECA FILES U.S. NDA FOR ZOMIG FAST MELT FORMULATION AND HAS GAINED APPROVAL IN 13 EUROPEAN COUNTRIES |
AstraZeneca today announced it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its fast melt formulation of Zomig for the acute treatment of migraine. The tablet melts within seconds on the tongue and provides migraineurs with a more convenient method of relieving their migraine.
|
|
31 May 2000
ASTRAZENECA EXTENDS MANUFACTURING AGREEMENT WITH SUMITOMO PHARMACEUTICALS TO BOOST 'Merrem/MERONEM'WORLD-WIDE SUPPLY |
AstraZeneca has extended an existing agreement with Sumitomo to significantly increase production for AstraZeneca's ultra-broad-spectrum antibiotic meropenem, known commercially as 'Merrem'and 'Meronem'. As a result of the agreement, the overall supply of 'Merrem/Meronem'is expected to double by 2003, with immediate supply in 2000 expected to increase by 40 per cent.
|
|
31 May 2000
ASTRAZENECA PLC ANNOUNCES THE RESULTS OF THE POLLS TAKEN AT ITS ANNUAL GENERAL MEETING ON FRIDAY 26 MAY 2000 |
AstraZeneca PLC announces the results of the polls taken at its Annual General Meeting on Friday 26 May 2000 in respect of Items 8 and 9 on the Agenda, as follows:
|
|
26 May 2000
TOM MCKILLOP'S SPEECH AT THE ASTRAZENECA AGM, 26TH MAY 2000 |
Download PDF of speech (602k Acrobat .pdf)
|
|
26 May 2000
PERCY BARNEVIK'S SPEECH AT THE ASTRAZENECA AGM, 26TH MAY |
Download PDF of speech (602k Acrobat .pdf)
|
|
24 May 2000
ASTRAZENECA's IRESSATM (ZD1839) DEMONSTRATES ENCOURAGING ANTI-TUMOUR ACTIVITY IN NON-SMALL CELL LUNG CANCER |
AstraZeneca today announced that final results from Phase I clinical trials of its novel anti-cancer compound known as Iressa™ or ZD1839, show, in a small number of patients, encouraging anti-tumour activity or disease stabilisation, particularly in non-small cell lung cancer. The data were presented at the American Society of Clinical Oncology (ASCO) annual meeting in New Orleans.
|
|
17 May 2000
STOCK EXCHANGE ANNOUNCEMENT ASTRAZENECA - EU COMPETITION AUTHORITY |
AstraZeneca confirms that the European Commission earlier this year made enquiries in February 2000 relating to AstraZeneca's defence of its intellectual property and other rights relating to omeprazole.
|
|
16 May 2000
ASTRAZENECA FILES LAWSUITS AGAINST EON LABS MANUFACTURING, INC. AND IMPAX LABORATORIES, INC. |
AstraZeneca filed lawsuits today in New York against Eon Labs Manufacturing, Inc. (Eon) and in Delaware against Impax Laboratories, Inc. (Impax) for patent infringement.
|
|
15 May 2000
FDA APPROVES ASTRAZENECA's STERILE FACILITY TO MANUFACTURE AND DISTRIBUTE MERREM I.V. |
CREATES INCREASED U.S. SUPPLY OF BROAD SPECTRUM ANTIBIOTIC
|
|
15 May 2000
FDA GRANTS ORPHAN DRUG STATUS TO ASTRAZENECA FOR MERREM® I.V. TO RESEARCH TREATMENT FOR CYSTIC FIBROSIS |
The U.S. Food and Drug Administration (FDA) announced today that it has granted AstraZeneca USA orphan drug status for its anti-infective medicine, Merrem® I.V. Currently, Merrem® I.V. is indicated in the USA for intra-abdominal infections in adults and children, and bacterial meningitis in children three months of age and older. Outside the USA, Merrem® is licensed for use in a wide range of infections.
|
|
25 April 2000
ASTRAZENECA OBTAINS FIRST APPROVAL FOR SELOKEN® ZOK FOR THE TREATMENT OF HEART FAILURE |
AstraZeneca today announced that the beta blocker, Seloken® ZOK, has gained its first approval for the treatment of heart failure, an important extension to the existing range of cardiovascular indications for Seloken® ZOK which include angina, hypertension and post-myocardial infarction. The licence approval was granted in Denmark and the company expects to gain further approvals in other European countries and the US later this year.
|
|
13 April 2000
ASTRAZENECA RECEIVES EUROPEAN APPROVAL OF ARIMIDEX® FOR FIRST-LINE TREATMENT OF POST-MENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER |
AstraZeneca today announced it has received approval from the UK and five other European countries to extend the use of Arimidex® into first line treatment for post menopausal women with advanced breast cancer.
|
|
11 April 2000
ASTRAZENECA FILES NDA FOR ZOMIG® (ZOLMITRIPTAN) - POTENTIALLY FIRST ORAL TRIPTAN IN JAPAN |
Japan, April 11, 2000: AstraZeneca today announced that it has submitted a new drug application for Zomig (zolmitriptan) for the acute treatment of migraine with or without aura. Potentially this could be the first oral triptan to be approved in Japan.
|
|
3 April 2000
ASTRAZENECA ONCOLOGY PIPELINE FEATURED AT AMERICAN ASSOCIATION OF CANCER RESEARCH (AACR) 2000 MEETING |
Novel approaches to selectively targeting the processes that make cancer cells grow are being prominently featured at this week's American Association of Cancer Research meeting in San Francisco, USA. Three of these 'novel approach' compounds - ZD1839 ('Iressa'), ZD6474 and ZD6126 - all products of the innovative research and in-licensing programme at AstraZeneca, will be featured.
|
|
21 March 2000
ASTRAZENECA TO APPEAL DECISION BY GERMAN PATENT COURT |
AstraZeneca today announced that the company will appeal a ruling handed down by the German Federal Patent Court. The Patent Court nullified the formulation patent for omeprazole in Germany. The patent covering the formulation, expiring in 2007, has been subject to nullity actions by the generic manufacturing companies Azupharma GmbH & Co and ratiopharm GmbH. Omeprazole is the active ingredient in Losec®.
|
|
21 March 2000
EU REVIEW OF SYNGENTA TRANSACTION EXTENDED: COMPLETION IN SECOND HALF 2000 STILL ANTICIPATED |
AstraZeneca PLC today confirmed that the European Commission has initiated a Second Phase Investigation into the proposed spin off and merger of its agrochemicals business with Novartis' crop protection and seeds business.
|
|
14 March 2000
FDA GRANTS ASTRAZENECA PRIORITY REVIEW FOR NOLVADEX® FOR TREATMENT OF DUCTAL CARCINOMA IN SITU (DCIS), A COMMON TYPE OF NON-INVASIVE BREAST CANCER |
The U.S. Food and Drug Administration (FDA) has granted a six-month priority review to AstraZeneca's breast cancer drug NOLVADEX® (tamoxifen citrate) for the adjuvant treatment of ductal carcinoma in situ (DCIS) in women following breast surgery and radiation. AstraZeneca filed a supplemental new drug application with the FDA for the DCIS indication in December 1999.
|
|
13 March 2000
ASTRAZENECA's NEXIUM® RECEIVES FAST FIRST APPROVAL IN SWEDEN WITH WIDE RANGE OF INDICATIONS |
AstraZeneca today announced the initial approval of Nexium® (esomeprazole) with fast clearance given by the Swedish Medical Product Agency (MPA) for a broad range of indications, including two new treatment approaches.
|
|
10 March 2000
ASTRAZENECA's OMEPRAZOLE SUBSTANCE PATENT UPHELD IN GERMANY |
AstraZeneca today welcomed a decision by the German Federal Patent Court to dismiss an attack on the substance patent for omeprazole. In Germany, AstraZeneca's substance patent for omeprazole expired in April 1999. As the patent still is the basis for the Supplementary Protection Certificate (SPC) in Germany, it has been subject to a nullity action by the company Merck-dura GmbH. Omeprazole is the active ingredient in Losec®.
|
|
8 March 2000
LARGEST EVER BETA-BLOCKER STUDY SHOWS ASTRAZENECA's TOPROL-XL/SELOKEN ZOK IMPROVES CHF PATIENTS SURVIVAL |
Results of an international study published today in the Journal of the American Medical Association (JAMA) show that adding AstraZeneca's beta-blocker Toprol-XL/Seloken ZOK to standard treatment in patients with congestive heart failure improved survival, reduced hospitalisations and improved patients' well-being. The MERIT-HF study (Metoprolol CR (controlled release) Randomised Intervention Trial in Heart Failure) is the largest heart failure trial ever completed, involving nearly 4000 patients, to evaluate the efficacy of a beta-blocker.
|
|
6 March 2000
ASTRAZENECA PLANS TO DIVEST UK PACKAGING SITE AT CORBY |
AstraZeneca plans to divest its UK packaging plant at Corby, Northamptonshire, as a going concern.
|
|
1 March 2000
ATACAND® PLUS HYPERTENSION TREATMENT GAINS EU APPROVAL |
AstraZeneca today announced that its new hypertension treatment Atacand® Plus has gained EU mutual recognition in 12 countries.
|
|
28 February 2000
ASTRAZENECA FILES SUPPLEMENTAL NEW DRUG APPLICATION WITH FDA FOR 'CASODEX' 150MG MONOTHERAPY FOR THE TREATMENT OF PROSTATE CANCER |
AstraZeneca today announced that a supplemental new drug application (sNDA) has been filed with the US Food and Drug Administration (FDA) for 'Casodex' 150mg monotherapy for the treatment of locally advanced, non-metastatic prostate cancer.
|
|
24 February 2000
FULL YEAR RESULTS 1999 |
Commentary (81k PDF file) and Figures (184k PDF file)
|
|
1 February 2000
ASTRAZENECA WELCOMES GERMAN SUPREME COURT DECISION TO REFER OMEPRAZOLE SPC CASE TO EUROPEAN COURT OF JUSTICE |
AstraZeneca today welcomed a decision by the German Supreme Court to refer a number of questions about the company's Supplementary Protection Certificate (SPC) for omeprazole to the European Court of Justice (ECJ).
|
|
4 January 2000
ASTRAZENECA's OXIS® TURBUHALER® GAINS EUROPEAN UNION APPROVAL FOR 'AS NEEDED' TREATMENT |
AstraZeneca PLC announced today that Oxis Turbuhaler® (formoterol) has been approved in the European Union (EU) for 'as needed' treatment of asthma symptoms in addition to normal maintenance treatment.
|
|